Cardiac amyloidosis is associated with very high morbidity and mortality. Only if treated early, cardiac amyloidosis responds well to therapy, and early recognition with a full differential diagnostic workup including multimodality imaging is therefore critical at first presentation. Closely meshed clinical monitoring and imaging are indispensable to ensure optimal individualized treatment. (Level of Difficulty: Beginner.).
Keywords: AL, amyloid light chain; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; EMB, endomyocardial biopsy; LGE, late gadolinium enhancement; LV, left ventricular; NT-pro-BNP, N-terminal pro–B-type natriuretic peptide; cardiac amyloidosis; cardiomyopathies; cardiovascular inflammation; endomyocardial biopsy; immunosuppressive therapy; myocardial imaging.
© 2019 The Authors.